Logo


Natco Pharma upbeat over US Patent Office's ruling on two of Copaxone patents

In August 2014, Mylan had filed the abbreviated new drug application for multiple sclerosis drug Copaxone 40 mg/ml with the US FDA

Natco Pharma

Hyderabad-based Natco Pharma on Thursday announced that the US Patent and Trademark Office(PTO) has ruled in favour of its marketing partner, Mylan, in its new trial proceedings on patentability and found all claims of two related Copaxone 40 mg/ml patents as unpatentable. In August 2014, Mylan had filed the abbreviated new drug application (ANDA) for multiple sclerosis drug Copaxone 40 mg/ml with the US Food and Drug Administration(US FDA), besides challenging the patent claims of the Teva which owns the drug. The ANDA filing by Mylan pertains to the longer acting Copaxone while ...